Why the study?
Does mechanical circulatory support with Impella or IABP reduce all-cause short-term mortality in patients undergoing high-risk PCI and/or with cardiogenic shock?
Does mechanical circulatory support with Impella or IABP reduce all-cause short-term mortality in patients undergoing high-risk PCI and/or with cardiogenic shock?
Neither Impella nor IABP decreased short-term mortality compared to no mechanical circulatory support in high-risk PCI or cardiogenic shock, and Impella increased major bleeding.
Answers are grounded in this paper and cite their sources.
Does not support routine Impella or IABP use to reduce short-term mortality in high-risk PCI or CS; confirms null effect versus no MCS.
Neither Impella nor IABP decreased all-cause short-term mortality when compared with no MCS for high-risk PCI and/or CS. Moreover, Impella increased major bleeding compared with no MCS.
No takes yet. Share an insight, caveat, or question.
Kuno et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: